CPChandni Patel

Chandni Patel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chandni Patel has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Understanding Cancer Clinical Trial Participation in Rural Communities: A Qualitative Focus Group Study

    by Yetunde Tagurum, Jennifer N. Wells, Vickie Cater, Gigi A. Gonzales, Kimberly J. Kiplagat, Heidy Pickles, Sandra Baer, Kelli Mills, Crystal Clark, Stanley Jean‐Charles, et al.

    Background: Participation in cancer clinical trials is essential for advancing oncologic care, yet enrollment among rural populations remains disproportionately low. These communities face many hurdles including geographical distance from medical centers, healthcare workforce shortages, and deep‐seated medical mistrust that may contribute to survival inequities. Aims: To address these gaps, a Research Navigator program was launched through the Florida Cancer Specialists & Research Institute to engage rural Florida residents in focus group sessions to identify barriers to trial participation. Methods: Utilizing the Integrated Behavioral and Socioecological Framework (IBSF), the study conducted five semi‐structured focus groups with 30 participants recruited from rural Florida counties. Participants included cancer survivors, advocates, caregivers, and those currently in treatment. Discussions centered on knowledge, experiences, perceived barriers, and willingness to participate in cancer clinical trials. Results: Although most participants expressed awareness of cancer clinical trials, focus group discussions revealed misconceptions regarding trial purpose, process, and accessibility. Across groups, commonly reported barriers to participation included limited access to reliable transportation, financial concerns, and mistrust of medical professionals and healthcare systems. Thematic analysis of focus group transcripts yielded four themes: (A) perception and lived experience, (B) trial information dissemination, (C) enrollment impediments, and (D) intervention strategies and implementation. Conclusion: In rural settings, decisions regarding cancer clinical trial participation are shaped by a complex interplay of trust, logistics, and information access. This study emphasizes the importance of viewing trials as routine care and suggests that navigator‐led outreach and patient‐centric technology are essential for creating equitable access.


  • Open Access

    Long-term outcomes of ivermectin-albendazole versus albendazole alone against soil-transmitted helminths: Results from randomized controlled trials in Lao PDR and Pemba Island, Tanzania

    by Ladina Keller, Sophie Welsche, Chandni Patel, Somphou Sayasone, Said M. Ali, Shaali M. Ame, Jan Hattendorf, Eveline Hürlimann, Jennifer Keiser

    Background: Preventive chemotherapy is the cornerstone of soil-transmitted helminth (STH) control. Long-term outcomes and adequate treatment frequency of the recently recommended albendazole-ivermectin have not been studied to date. Methodology/principal findings: Double-blind randomized controlled trials were conducted in Lao PDR, Pemba Island, Tanzania and Côte d’Ivoire between 2018 and 2020 to evaluate the efficacy and safety of ivermectin-albendazole versus albendazole-placebo in Trichuris trichiura-infected individuals aged 6 to 60. In the framework of this study, in Lao PDR 466 and 413 participants and on Pemba Island, 558 and 515 participants were followed-up six and 12 months post-treatment, respectively. From each participant at least one stool sample was processed for Kato-Katz diagnosis and cure rates (CRs), egg reduction rates (ERRs) and apparent reinfection rates were calculated. If found helminth-positive at six months, participants were re-treated according to their allocated treatment. Long-term outcomes against T. trichiura based on CRs and ERRs of ivermectin-albendazole compared to albendazole were significantly higher at six months in Lao PDR (CR, 65.8 vs 13.4%, difference; 52.4; 95% CI 45.0–60.0; ERRs, 99.0 vs 79.6, difference 19.4; 95% CI 14.4–24.4) and Pemba Island (CR, 17.8 vs 1.4%, difference; 16.4; 95% CI 11.6–21.0; ERRs, 84.9 vs 21.2, difference 63.8; 95% CI 50.6–76.9) and also at 12 months in Lao PDR (CR, 74.0 vs 23.4%, difference; 50.6; 95% CI 42.6–61.0; ERRs, 99.6 vs 91.3, difference 8.3; 95% CI 5.7–10.8) and Pemba Island (CR, 19.5 vs 3.4%, difference; 16.1; 95% CI 10.7–21.5; ERRs, 92.9 vs 53.6, difference 39.3; 95% CI 31.2–47.4) respectively. Apparent reinfection rates with T. trichiura were considerably higher on Pemba Island (100.0%, 95% CI, 29.2–100.0) than in Lao PDR (10.0%, 95% CI, 0.2–44.5) at 12 months post-treatment for participants treated with albendazole alone. Conclusions/significance: The long-term outcomes against T. trichiura of ivermectin-albendazole are superior to albendazole in terms of CRs and ERRs and in reducing infection intensities. Our results will help to guide decisions on how to best use ivermectin-albendazole in the context of large-scale PC programs tailored to the local context to sustainably control STH infections. Trial registration: ClinicalTrials.gov registered with clinicaltrials.gov, reference: NCT03527732, date assigned: 17 May 2018.